
WGS Stock Forecast & Price Target
WGS Analyst Ratings
Bulls say
GeneDx Holdings is well-positioned to take advantage of the growing trend towards genomic testing, with a focus on pediatric and rare diseases. The company's plans to triple its sales force and expand into new markets, such as the pediatrician market and newborn screening, shows its commitment to growth and profitability. Although it may take time for these new opportunities to translate into revenue, GeneDx has a strong foundation and expertise in genomic testing, making it a promising investment for the future.
Bears say
GeneDx Holdings is facing several key risks, including hesitation from geneticists to fully adopt exome and genome testing, slow growth in the rare disease market and dependence on reimbursement decisions from clinicians. The recent quarter was disappointing, with revenue and gross margin missing expectations due to mix and softness in the non-core business. The company has lowered its guidance and our estimates for 2026-2028, and it will take time for its latest study results and expanded testing capabilities to potentially drive future growth and adoption in the market.
This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.
WGS Analyst Forecast & Price Prediction
Start investing in WGS
Order type
Buy in
Order amount
Est. shares
0 shares